Hormone Optimization Research Peptides: GH and HPG Axes Compared

Hormone optimization research peptides fall into two broad groups by the axis they act on. Growth hormone axis compounds include tesamorelin, CJC-1295, ipamorelin, and sermorelin, which act at the hypothalamic and pituitary level of GH release. HPG axis compounds include kisspeptin, which acts upstream of GnRH neurons in the hypothalamus. These are separate systems with separate receptors, and treating them as one category is where most confusion starts. Research use only.

Two axes, not one category

Search “hormone optimization peptides” and you’ll land on pages that lump together compounds with almost nothing in common mechanistically. That’s the core problem with how this topic usually gets covered. Tesamorelin has nothing structurally to do with kisspeptin. They don’t share a receptor, a release pathway, or even the same gland as their primary target.

The growth hormone (GH) axis runs from the hypothalamus to the anterior pituitary to the liver. Hypothalamic GHRH neurons release growth hormone releasing hormone, which binds the GHRH receptor on pituitary somatotrophs and triggers GH secretion. GH then travels to the liver, where it drives IGF-1 production. A second, parallel input comes from ghrelin receptor signaling, which amplifies GH pulses through a separate mechanism. Tesamorelin, CJC-1295, and sermorelin work on the GHRH receptor side. Ipamorelin and GHRP-6 work on the ghrelin receptor side. Four different molecules, two different entry points into the same downstream pathway.

The hypothalamic-pituitary-gonadal (HPG) axis is a separate circuit. It starts with kisspeptin neurons in the hypothalamus, which sit upstream of GnRH neurons and control their pulsatile firing. GnRH then drives pituitary LH and FSH release, which in turn signal the gonads. Kisspeptin’s receptor, GPR54 (also called KISS1R), was identified as essential to pubertal onset when researchers found that loss-of-function mutations in the gene blocked puberty entirely in the affected cohort studied (Seminara et al., N Engl J Med, 2003. PMID: 14573733). That’s a fundamentally different biological question than anything the GH axis compounds are studied for.

Here’s the part that trips people up: both axes technically originate in the same anatomical neighborhood. The hypothalamus houses both the GHRH neurons that feed the GH axis and the kisspeptin neurons that feed the HPG axis, and both send projections toward the pituitary gland sitting just below it. Proximity gets mistaken for overlap. It isn’t. GHRH neurons and kisspeptin neurons are distinct cell populations with different genetic markers, different firing patterns, and no direct synaptic connection driving one from the other under normal conditions.

So when a search brings up “cjc 1295 ipamorelin blend” next to “kisspeptin,” it’s not because the compounds relate biologically. It’s because both get filed under a vague marketing umbrella term that never got broken apart. This page does that work. It splits the two axes into their own sections, explains the mechanism class within each, and routes to the deeper pages that actually cover each compound in full. Think of this as the map, not the destination.

Explore the complete research compound catalogue for the full list of peptides studied across both axes and beyond.

Growth hormone axis research compounds

Four compounds dominate the GH axis literature and search interest: tesamorelin, CJC-1295, ipamorelin, and sermorelin. Each has a dedicated page covering its full mechanism, pharmacokinetic profile, and research history. This section gives the short version of each and sends you to the long version.

Tesamorelin

Tesamorelin is a synthetic analogue of GHRH, engineered with a stabilized N-terminus that resists rapid enzymatic breakdown. It binds the pituitary GHRH receptor and stimulates a GH pulse that follows the same downstream IGF-1 pathway as the endogenous hormone. In a randomized controlled trial in obese adults with reduced GH secretion, a GHRH analogue in this class raised GH pulse amplitude without materially disrupting glucose handling over the study period (Makimura et al., J Clin Endocrinol Metab, 2012. PMID: 23015655). Spartan carries tesamorelin as a research compound, and the full mechanism writeup lives in the tesamorelin growth hormone axis research guide.

CJC-1295

CJC-1295 is also a GHRH analogue, but with a different modification strategy: a drug affinity complex (DAC) that binds serum albumin and extends its circulating half-life far past native GHRH or tesamorelin. In the original human pharmacokinetic study, a single injection produced elevated GH and IGF-1 levels that persisted across a multi-day observation window rather than the minutes typical of unmodified GHRH (Teichman et al., J Clin Endocrinol Metab, 2006. PMID: 16352683). That extended duration is the main reason it gets studied alongside ipamorelin rather than alone. See how tesamorelin and CJC-1295 compare in growth hormone research for the side by side breakdown.

Ipamorelin

Ipamorelin works through an entirely different receptor: the ghrelin receptor (GHS-R1a), not the GHRH receptor. It was characterized in 1998 as the first GH secretagogue shown to stimulate GH release selectively, with no meaningful cross-reactivity on cortisol, prolactin, or ACTH secretion in the animal models tested, a selectivity problem that had dogged earlier ghrelin receptor agonists like GHRP-6 (Raun et al., Eur J Endocrinol, 1998. PMID: 9849822). That selectivity profile is why it’s the most commonly paired secretagogue in combination research protocols. The CJC-1295 and ipamorelin research blend is the combined format Spartan carries. Full mechanism detail is in the CJC-1295 and ipamorelin blend research guide.

Sermorelin

Sermorelin is the shortest of the four: a 29-amino-acid fragment, GRF(1-29), that represents the minimum sequence needed to fully activate the GHRH receptor. Everything past residue 29 in native GHRH (the hormone runs 44 residues in its full form) turns out to be unnecessary for receptor binding, which is a useful fact on its own. It tells you the GHRH receptor’s binding pocket only reads the first third of the molecule. Sermorelin’s pituitary stimulation profile has been reviewed as a lower-intensity, shorter-acting alternative to longer analogues in the same GHRH receptor class, useful for research protocols that want a cleaner pulse rather than sustained elevation (Walker, Clin Interv Aging, 2006. PMID: 18046908). It’s the closest thing to a baseline reference compound in GHRH receptor pharmacology. Shorter half-life, simpler structure, and that’s exactly why so many comparison studies use it as the control arm rather than the experimental variable.

GHRH analogues versus GH secretagogues

This is the distinction that “ghrp 6 vs tesamorelin” searches are actually asking about, and it’s underserved almost everywhere online. Tesamorelin, CJC-1295, and sermorelin are GHRH analogues. They bind the GHRH receptor directly and mimic the hypothalamus’s own signal to the pituitary.

Ipamorelin and GHRP-6 are GH secretagogues. They bind the ghrelin receptor, a completely separate receptor on the same pituitary cell, and amplify GH release through a parallel pathway. The catch: secretagogue signaling isn’t fully independent of GHRH input. In one classic study, blocking endogenous GHRH signaling substantially blunted the GH response to GHRP-6, showing that the ghrelin receptor pathway needs a functioning GHRH signal in the background to produce its full effect (Pandya et al., J Clin Endocrinol Metab, 1998. PMID: 9543138).

That interaction is the whole rationale behind combining a GHRH analogue with a secretagogue in research protocols. One drives the primary GH pulse. The other amplifies it through a second receptor that depends partly on the first pathway being active. Run either alone and you get a smaller effect than running both together, at least based on the receptor pharmacology.

Where does GHRP-6 fit into all this? It was one of the earlier ghrelin receptor agonists characterized, predating ipamorelin by roughly a decade, and it shares ipamorelin’s receptor target but not its selectivity. GHRP-6 also raises cortisol and prolactin alongside GH in animal studies, a broader hormonal footprint than ipamorelin’s narrower profile. Researchers comparing the two are typically weighing that tradeoff: a compound with a longer research history against one with a cleaner mechanism. Neither is a GHRH analogue, and neither substitutes for one; they’re both operating one step downstream on the ghrelin receptor side of the diagram.

HPG axis research compounds

Kisspeptin is the primary HPG axis compound in the current research catalogue. Structurally and mechanistically it has nothing in common with the GH axis compounds above, which is exactly why it needs its own section rather than a shared page.

Kisspeptin neurons in the hypothalamus sit directly upstream of GnRH neurons and control their pulsatile activity. Kisspeptin binds GPR54 on GnRH neurons, triggering GnRH release, which then drives pituitary LH and FSH secretion. Two independent human genetics findings established this pathway as essential rather than incidental: loss-of-function GPR54 mutations block pubertal onset entirely (de Roux et al., PNAS, 2003. PMID: 12944565), and a separate cohort study confirmed the same receptor as the genetic basis of a specific inherited form of hypogonadotropic hypogonadism (Seminara et al., N Engl J Med, 2003. PMID: 14573733).

Enclomiphene is often searched alongside kisspeptin, but it works through an entirely different mechanism: it’s a selective estrogen receptor modulator that acts at the hypothalamus and pituitary to interrupt negative feedback, rather than an upstream GnRH trigger like kisspeptin. It’s not a peptide at all, for that matter, it’s a small molecule, structurally closer to a modified steroid scaffold than to the 10 or 54-amino-acid kisspeptin fragments used in research. The two get compared constantly because they sit at similar points in the reproductive endocrine research literature, not because they share a receptor or a chemical class. The full comparison, including mechanism, structure, and research application differences, is covered in kisspeptin and enclomiphene mechanisms compared. Spartan carries kisspeptin-10 as a research compound for investigators working in this space, and it’s worth noting that kisspeptin research uses several fragment lengths (10, 14, and 54-amino-acid forms appear across the literature), each retaining GPR54 binding activity but with different stability profiles.

Comparison table across both axes

Compound	Axis	Mechanism class	Dedicated page
Tesamorelin	GH	GHRH receptor agonist	Research guide
CJC-1295	GH	GHRH receptor agonist, extended half-life (DAC)	Comparison guide
Ipamorelin	GH	Selective ghrelin receptor agonist	Research guide
Sermorelin	GH	GHRH receptor agonist, minimal fragment (1 to 29)	Research guide
GHRP-6	GH	Ghrelin receptor agonist	Related research compounds
Kisspeptin	HPG	GPR54 (KISS1R) agonist, upstream of GnRH	Comparison guide

How these compounds are studied together

Combination research is common within the GH axis, less so across axes. The most frequently studied combination is a GHRH receptor agonist paired with a ghrelin receptor agonist, since the two act on separate receptors that converge on the same pituitary somatotroph. CJC-1295 plus ipamorelin is the most established version of this pairing in the current literature, driven by the receptor interaction described above.

Cross-axis combinations (a GH axis compound alongside kisspeptin) show up far less in published research, mostly because the biological questions rarely overlap. GH axis work centers on somatotroph output, metabolism, and IGF-1 signaling. HPG axis work centers on gonadotropin pulsatility and reproductive endocrinology. There’s no obvious mechanistic reason to study them in the same protocol, and the current literature reflects that split. That doesn’t mean the two axes never talk to each other physiologically (GH status can influence reproductive hormone tone in some contexts, and vice versa) but that’s a downstream systems-level interaction, not a shared receptor or a design rationale for a combined research protocol.

Duration profile matters more than most people expect when comparing GH axis compounds for a study design. Sermorelin’s short half-life makes it useful when a researcher wants a defined, discrete pulse to measure against a baseline. CJC-1295’s extended half-life does the opposite: it flattens the pulsatile pattern into something closer to a sustained elevation, which changes what a study can actually observe about downstream IGF-1 kinetics. Neither profile is better in the abstract. They answer different questions, and picking the wrong one for a given research design is a common and avoidable mistake.

Spartan’s CJC and tesamorelin growth hormone stack reflects the same-axis pairing logic: two GHRH receptor agonists with different pharmacokinetic profiles, studied together to characterize how a fast-acting and a long-acting analogue interact. For a broader look at how researchers approach multi-compound protocols generally, see the guide to combining research peptides.

Frequently asked questions

What is the difference between the growth hormone axis and the HPG axis?

The GH axis runs from hypothalamic GHRH through the pituitary to GH and IGF-1 output, affecting metabolism and tissue growth pathways broadly. The HPG axis runs from hypothalamic kisspeptin and GnRH through the pituitary to LH and FSH, affecting gonadal signaling specifically. They share the hypothalamus and pituitary as anatomical structures but use different neurons, different releasing hormones, and different downstream targets. If a study is measuring IGF-1, it’s GH axis work. If it’s measuring LH pulsatility, it’s HPG axis work. That single distinction resolves most of the confusion in this space.

What is a GHRH analogue?

A GHRH analogue is a synthetic compound engineered to bind the same pituitary GHRH receptor as native growth hormone releasing hormone, either matching or modifying the natural sequence to change stability or duration of action. Tesamorelin, CJC-1295, and sermorelin all fall into this class, each with a different modification strategy.

How do GH secretagogues differ from GHRH analogues?

GH secretagogues like ipamorelin and GHRP-6 bind the ghrelin receptor (GHS-R1a), a separate receptor from GHRH’s target, and amplify GH release through a parallel pathway. GHRH analogues activate the GHRH receptor directly. Research shows the secretagogue pathway partially depends on background GHRH signaling to produce its full effect, which is the mechanistic basis for combination protocols.

How does tesamorelin differ from CJC-1295?

Both are GHRH receptor agonists, but they use different stabilization strategies. Tesamorelin has a modified N-terminus that slows enzymatic breakdown. CJC-1295 uses a drug affinity complex that binds serum albumin, extending its circulating presence across days rather than minutes. The full side by side comparison is in the tesamorelin versus CJC-1295 research guide.

Where does kisspeptin act?

Kisspeptin acts on GPR54 receptors located on GnRH neurons in the hypothalamus, upstream of the pituitary. It doesn’t act on the pituitary directly. Its effect on downstream LH and FSH secretion is mediated entirely through its control of GnRH neuron firing.

Are these compounds approved for medical use?

Tesamorelin has FDA approval for a narrow clinical indication unrelated to the research applications discussed on this page. CJC-1295, ipamorelin, sermorelin, GHRP-6, and kisspeptin are not FDA-approved compounds and are sold and studied strictly as research chemicals. Approval status for one specific formulation doesn’t extend to the broader compound class or to any other analogue discussed here. Nothing on this page describes or endorses human administration of any compound listed.

What does research-use-only mean?

Research-use-only means a compound is manufactured and sold exclusively for laboratory investigation, in vitro study, or use in animal research models by qualified researchers and institutions. It is not intended for human consumption, diagnostic use, or any clinical application, and Spartan Peptides does not provide dosing, administration, or usage guidance for humans.

Research Use Only

All compounds referenced on this page are sold strictly for laboratory research purposes. They are not drugs, food products, or cosmetics, and are not intended for human or animal consumption. Nothing on this page constitutes medical advice or a recommendation for human use.